Disease activity assessment in SLE: do we have the right instruments?

Area of Science:

• Rheumatology
• Clinical Trial Design
• Drug Development

Background:

• No new systemic lupus erythematosus (SLE) therapies have been approved in decades.
• Despite increased pharmaceutical interest and numerous clinical trials, many SLE drug development efforts have failed.
• A significant concern is that several failed therapies showed promising efficacy signals, particularly in subgroup analyses.

Purpose of the Study:

• To investigate the reasons behind the high failure rate of clinical trials for systemic lupus erythematosus (SLE).
• To examine whether "failed" SLE therapies demonstrated potential efficacy in specific patient subgroups.
• To raise concerns regarding the adequacy of current SLE clinical trial designs and disease activity indices.

Main Methods:

• Review of historical clinical trial data for systemic lupus erythematosus (SLE) therapies.
• Analysis of subgroup efficacy data from "failed" SLE clinical trials.
• Evaluation of the mechanistic rationale for investigated SLE therapies.

Main Results:

• Multiple clinical trials for SLE have concluded without leading to new therapy approvals.
• Many "failed" SLE treatments exhibited "signals" of efficacy, often supported by logical subgroup analyses.
• The observed efficacy signals in subgroup analyses suggest potential issues beyond the therapy's actual effectiveness.

Conclusions:

• There is a growing concern that systemic lupus erythematosus (SLE) clinical trial designs may be flawed.
• Existing SLE disease activity indices might not be adequately capturing treatment efficacy.
• Further investigation into optimizing SLE trial methodologies is warranted to improve drug development success rates.